Business

Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025 35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non

articleIntelligent Bio Solutions Inc.May 13, 202510/company/intelligent-bio-solutions-inc/news/intelligent-bio-solutions-announces-fiscal-123000469
Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

About this update from Intelligent Bio Solutions Inc.

[{"type":"image","alt":"Intelligent Bio Solutions, Inc.","displaySize":"","headline":null,"caption":"Intelligent Bio Solutions, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":53,"url":"https://media.zenfs.com/en/globenewswire.com/9eadf03086af52dd7cf59a7dde9f27c4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dyf1dhe.u4apapwa.JaM4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/9eadf03086af52dd7cf59a7dde9f27c4","width":300,"height":53}},"lazy":false},{"type":"text","content":"20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth","length":92,"tagName":"p"},{"type":"text","content":"Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025 ","length":136,"tagName":"p"},{"type":"text","content":"35 new accounts and international growth during Q3 bring total active accounts to over 450","length":90,"tagName":"p"},{"type":"text","content":"NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update. ","length":345,"tagName":"p"},{"type":"text","content":"The Company delivered a strong quarter of growth in revenue compared to the previous quarter, supported by ongoing expansion across safety-critical industries and steady customer acquisition. Cartridge sales, a key contributor to margin improvement, continue to make up a growing share of income, contributing 58% of total revenue for the fiscal year to March 31, 2025, and strengthening the Company’s recurring revenue model. With 35 new customers added during the quarter and an active customer base now surpassing 450 accounts, INBS remains on track with its plans to scale its commercial footprint and international presence ahead of its expected entry into the U.S. market.","length":678,"tagName":"p"},{"type":"text","content":"During the fiscal third quarter, the Company advanced its international growth strategy and product readiness through a series of targeted initiatives. These included expanded access in key Eur...

More updates from Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc.The CompanyIntelligent Bio Solutions IncIntelligent BioIntelligent Fingerprintingtotal revenuenine months